Effects of Dextran Sulfate Sodium-Induced Ulcerative Colitis on the Disposition of Tofacitinib in Rats

Tofacitinib, a Janus kinase 1 and 3 inhibitor, is mainly metabolized by CYP3A1/2 and CYP2C11 in the liver. The drug has been approved for the chronic treatment of severe ulcerative colitis, a chronic inflammatory bowel disease. This study investigated the pharmacokinetics of tofacitinib in rats with...

Descripción completa

Detalles Bibliográficos
Autores principales: Bae, Sung Hun, Kim, Hyo Sung, Choi, Hyeon Gyeom, Chang, Sun-Young, Kim, So Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Applied Pharmacology 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622310/
https://www.ncbi.nlm.nih.gov/pubmed/35811297
http://dx.doi.org/10.4062/biomolther.2022.049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622310/
https://www.ncbi.nlm.nih.gov/pubmed/35811297
http://dx.doi.org/10.4062/biomolther.2022.049

Ejemplares similares